Recent

% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • juststent3195 juststent3195 May 7, 2004 2:04 PM Flag

    Stent Modification

    That is a Return on investment issue that both companies face. That is not a product malfuncting like the Taxus system is doing. The nature of the DES business initially is costly for both companies. At least a third of boston stents currently on the shelf expire at the end of May. This short shelf life is a costly part of business that affect both companies bottom line.

    Cordis will worry about expiring stents, both company will try to keep it to a minimum. BSX has to worry that this malfunctioning events may or may not continue. IMHO the later is greater.

    So what else you got?

 
BSX
23.655-0.065(-0.27%)1:09 PMEDT